# OCUL catalysts: OCULAR THERAPEUTIX, INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ocul/catalysts

> OCULAR THERAPEUTIX, INC (OCUL) has 10 upcoming catalysts. The next is the PAVBLU® (aflibercept) topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for OCUL?

OCULAR THERAPEUTIX, INC (OCUL) has 10 upcoming catalysts. The next is the PAVBLU® (aflibercept) topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027" [Calendar and source filings](https://sec-api.dev/companies/ocul/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-055241, https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-05-05. Cite: https://sec-api.dev/companies/ocul/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | OCULAR THERAPEUTIX, INC |
| Ticker | OCUL (Nasdaq) |
| SEC CIK | 1393434 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ocul |

## Cash runway

Cash $530.6M as of 2026-09-30; quarterly burn $65.6M; about 24.3 months of runway at that rate (XBRL company facts, accession 0001104659-26-124155).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 21, 2016 | [Dextenza (dexamethasone) complete response letter (CRL)](https://sec-api.dev/pdufa/dexamethasone) | OCUL |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208742_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| July 10, 2017 | [Dextenza (dexamethasone) complete response letter (CRL)](https://sec-api.dev/pdufa/dexamethasone) | OCUL |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208742_2018_Orig1s000OtherActionLtrs.pdf%22)) |
| November 30, 2018 | [Dextenza (dexamethasone) FDA approval](https://sec-api.dev/pdufa/dexamethasone) | OCUL |  | completed, approved | "NDA208742 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20181130, review_priority STANDARD; sponsor_name OCULAR THERAPEUTIX; product DEXTENZA (DEXAMETHASONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208742%22)) |
| October 7, 2021 | [Dextenza (dexamethasone) label expansion decision](https://sec-api.dev/pdufa/dexamethasone) | OCUL |  | completed, approved | "NDA208742 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20211007, review_priority STANDARD; sponsor_name OCULAR THERAPEUTIX; product DEXTENZA (DEXAMETHASONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208742%22)) |
| November 14, 2024 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the third quarter ended September 30, 2024 and provided recent business highlights, including an update on the Phase 3 registrational program for AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) in development for wet age-related macular degeneration (wet AMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/tm2428320d2_ex99-1.htm)) |
| March 3, 2025 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today reported financial results for the fourth quarter and year ended December 31, 2024 and provided recent business highlights, including updates to the registrational program for AXPAXLI™ (axitinib intravitreal hydrogel) in wet age-related macular degeneration (wet AMD) designed to accelerate a potential path to NDA submission and increased label flexibility." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/tm258051d1_ex99-1.htm)) |
| April 7, 2025 | [Dextenza (dexamethasone) label expansion decision](https://sec-api.dev/pdufa/dexamethasone) | OCUL |  | completed, approved | "NDA208742 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20250407, review_priority STANDARD; sponsor_name OCULAR THERAPEUTIX; product DEXTENZA (DEXAMETHASONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208742%22)) |
| May 5, 2025 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "(NASDAQ: OCUL, "Ocular"), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/tm2513949d1_ex99-1.htm)) |
| August 5, 2025 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Inc. (NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the second quarter ended June 30, 2025, and provided recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_ex99-1.htm)) |
| Q4 2025 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | OCUL |  | scheduled | "We expect the SOL-1 trial to be fully enrolled with all subjects randomized by the end of 2024 and to present topline data from the SOL-1 trial during the fourth quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1393434/000155837024015613/ocul-20240930x10q.htm)) |
| Nov 2025 | [Diabetic trial start](https://sec-api.dev/pdufa/diabetic) | OCUL |  | completed | "We commenced our HELIOS registrational program for AXPAXLI for the treatment of diabetic retinal disease with the initiation of the Phase 3 HELIOS-3 superiority clinical trial for the treatment of NPDR in November 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/ocul-20251231x10k.htm)) |
| November 4, 2025 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "(NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the third quarter ended September 30, 2025 and provided recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_ex99-1.htm)) |
| Q1 2026 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | OCUL |  | scheduled | "Exceptional execution and retention in AXPAXLI wet AMD registrational program continue with topline data on track for SOL-1 in 1Q 2026 and SOL-R in 1H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_ex99-1.htm)) |
| Q1 2026 | [OCULAR THERAPEUTIX, INC topline data readout](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | scheduled | "The Company expects to report top-line data from year 1 of the SOL-1 clinical trial during the first quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1393434/000110465925118940/tm2532882d1_8k.htm)) |
| Feb 2026 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | OCUL |  | completed, positive | "SOL-1 (Phase 3, wet AMD) superiority trial on track for topline data in the second half of February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_ex99-1.htm)) |
| February 5, 2026 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_ex99-1.htm)) |
| April 2026 | [Otx-tki (axitinib implant) primary completion](https://sec-api.dev/pdufa/otx-tki-axitinib-implant) | OCUL | Neovascular Age-Related Macular Degeneration | delayed | "NCT06223958 (Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-29 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06223958)) |
| May 5, 2026 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "(NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm)) |
| Q3 2026 | [PAVBLU® (aflibercept) NDA/BLA submission](https://sec-api.dev/pdufa/aflibercept) | OCUL |  | scheduled | "Pre-NDA meeting scheduled with FDA in Q3 2026 with the NDA submission to follow the Section 505(b)(2) pathway which could accelerate the review timeline by up to 60 days" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm)) |
| August 3, 2026 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm)) |
| November 9, 2026 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926124151/tm2629079d2_ex99-1.htm)) |
| Q1 2027 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | OCUL |  | scheduled | "SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm)) |
| Q1 2027 | [OCULAR THERAPEUTIX, INC topline data readout](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | scheduled | "Topline data for the SOL-R trial are expected to be available in the first quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1393434/000110465926055256/ocul-20260331x10q.htm)) |
| Q1 2027 | [OCULAR THERAPEUTIX, INC topline data readout](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | scheduled | "Obtain additional clinical data from the continuation of the SOL-1 trial through the end of Week 104 and the continuation of the SOL-R Phase 3 clinical trial, for which we intend to report topline data on the primary efficacy endpoint in the first quarter of 2027, and the planned SOL-X trial, which we intend to initiate in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/ocul-20251231x10k.htm)) |
| Jan to Apr 2027 | [Otx-tki topline data readout](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-related Macular Degeneration | scheduled | "NCT06495918 (Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06495918)) |
| January 2027 | [Otx-tki primary completion](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-related Macular Degeneration | scheduled | "NCT06495918 (Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06495918)) |
| March 2027 | [Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at week 24 primary completion](https://sec-api.dev/pdufa/single-intravitreal-injection-of-axitinib-hydrogel-implant-followed-by-a-mock-sh) | OCUL | Non-Proliferative Diabetic Retinopathy | scheduled | "NCT07235085 (A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07235085)) |
| Mar to Jun 2027 | [Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at week 24 topline data readout](https://sec-api.dev/pdufa/single-intravitreal-injection-of-axitinib-hydrogel-implant-followed-by-a-mock-sh) | OCUL | Non-Proliferative Diabetic Retinopathy | scheduled | "NCT07235085 (A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07235085)) |
| Q1 2028 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | OCUL |  | scheduled | "SOL-R primary endpoint timing updated to Week 40 with topline results on track for 1Q 2028 after key secondary endpoints are evaluated." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926124151/tm2629079d2_ex99-1.htm)) |
| August 2030 | [Otx-tki primary completion](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-Related Macular Degeneration (nAMD) | scheduled | "NCT07516132 (Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-01 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07516132)) |
| Aug to Nov 2030 | [Otx-tki topline data readout](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-Related Macular Degeneration (nAMD) | scheduled | "NCT07516132 (Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-01 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07516132)) |

## Drugs

- [Dextenza (dexamethasone)](https://sec-api.dev/pdufa/dexamethasone): ataxia-telangiectasia
- [Diabetic](https://sec-api.dev/pdufa/diabetic): 
- [Otx-tki](https://sec-api.dev/pdufa/otx-tki): Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)
- [Otx-tki (axitinib implant)](https://sec-api.dev/pdufa/otx-tki-axitinib-implant): Neovascular Age-Related Macular Degeneration
- [Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at week 24](https://sec-api.dev/pdufa/single-intravitreal-injection-of-axitinib-hydrogel-implant-followed-by-a-mock-sh): Non-Proliferative Diabetic Retinopathy

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ocul/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OCUL catalysts: OCULAR THERAPEUTIX, INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ocul/catalysts

```bibtex
@misc{secapidev_companies_ocul_catalysts_20261116,
  title        = {OCUL catalysts: OCULAR THERAPEUTIX, INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ocul/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ocul_catalysts_20261116","title":"OCUL catalysts: OCULAR THERAPEUTIX, INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ocul/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
